Patent · US Active

Soluble mediator

US10413589B2 · kind B2 · utility

1Cited by
2References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 12, 2018
Grant dateSep 17, 2019
Priority date
Expiry dateDec 12, 2038

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type I diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.